# US 10,478,403 B1 · Intraoperative topically-applied non-implantable rapid release patch

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 10,478,403 B1
- Document ID: US10478403B1
- Status: Granted
- Kind: B1
- Application number: 15/970,513
- Filed: 2018-05-03
- Granted: 2019-11-19
- Earliest claimed: 2017-05-03
- Assignees: Privo Technologies, Inc.
- Applicants: Privo Technologies, Inc.
- Inventors: Manijeh Nazari Goldberg; Brandon LaPorte; Aaron Manzi; Amani Jahjaa
- Web page: https://patentgrep.com/patent/US10478403B1

## CPC

- A61K 9/7007: {Drug-containing films, membranes or sheets (A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence)}
- A61K 9/0024: {Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L)}
- A61K 9/5036: {Polysaccharides, e.g. gums, alginate; Cyclodextrin}
- A61K 9/5161: {Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin}
- A61K 9/7023: {Transdermal patches and similar drug-containing composite devices, e.g. cataplasms (galenical aspects of iontophoretic devices A61K9/0009; microneedle arrays A61K9/0021; buccal patches A61K9/006)}
- A61K 31/722: Chitin, chitosan
- A61K 47/36: Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61L 15/28: Polysaccharides or their derivatives {(A61L15/225 takes precedence)}
- A61L 15/425: {Porous materials, e.g. foams or sponges}
- A61L 15/44: Medicaments
- A61L 15/46: Deodorants or malodour counteractants, e.g. to inhibit the formation of ammonia or bacteria
- A61L 26/0023: {Polysaccharides}
- A61L 26/0066: {Medicaments; Biocides}
- A61L 26/0085: {Porous materials, e.g. foams or sponges}
- A61L 26/0095: {Composite materials, i.e. containing one material dispersed in a matrix of the same or different material}
- A61L 27/34: Macromolecular materials
- A61L 2300/602: Type of release, e.g. controlled, sustained, slow
- A61L 2300/622: Microcapsules
- A61L 2300/624: Nanocapsules
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61L: METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES (preservation of bodies or disinfecting characterised by the agents employed A01N; preserving, e.g. sterilising, food or foodstuffs A23; preparations for medical, dental or toiletry purposes A61K)

## Abstract

A device for delivery of a therapeutic agent to a surgical cavity, including: a porous, mucoadhesive, freeze-dried polymeric matrix having first and second opposed surfaces, the matrix formed by a composition including chitosan; a plurality of particles embedded within the matrix, the particles containing the therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan; and an additive selected from the group consisting of a hydration promoter, a particle adhesion inhibitor, a particle aggregation inhibitor, and combinations thereof. The first surface of the matrix is configured to be applied to the surgical cavity; the device releases the particles through the first surface; the device is also sterilized and provides release of approximately 20% to 100% of the therapeutic agent within 20 minutes of application to the surgical cavity.

## Claims

### Claim 1

A device for rapid delivery of a therapeutic agent to a surgical cavity, the device comprising:
a porous, mucoadhesive, freeze-dried polymeric matrix having first and second opposed surfaces, the matrix formed by a composition comprising chitosan, and a particle adhesion inhibitor, comprising hydroxypropylmethylcellulose (HPMC);
a plurality of particles, having an average diameter between 500 nm and 2000 nm, embedded within the matrix so as to be directly surrounded by, and in contact with, the matrix, the particles containing the therapeutic agent and having a coating around the therapeutic agent, the coating comprising chitosan so as to provide controlled release of the therapeutic agent from the particles through the first opposed surface of the matrix; and
one or more additives selected from the group consisting of a hydration promoter, a particle aggregation inhibitor, and combinations thereof,
wherein:
the first surface of the matrix is configured to be applied to the surgical cavity;
the device is configured to provide release of the particles through the first surface;
the device is sterilized;
the device provides release of approximately 20% to 100% of the therapeutic agent within 20 minutes of application to the surgical cavity, and
the particle adhesion inhibitor, and, when present, the hydration promoter, and the particle aggregation inhibitor are compounds mutually distinct from one another and present in amounts sufficient to achieve the controlled release of the particles without preventing formation of the freeze-dried matrix.

### Claim 2 (depends on 1)

A device according to claim 1, wherein the hydration promoter is selected from the group consisting of ethylene glycol, propylene glycol, beta-propylene glycol, glycerol and combinations thereof.

### Claim 3 (depends on 1)

A device according to claim 1, wherein the particle aggregation inhibitor is selected from the group consisting of monosaccharides, disaccharides, sugar alcohols, chlorinated monosaccharides, chlorinated disaccharides, and combinations thereof.

### Claim 4 (depends on 1)

A device according to claim 1, wherein the particles further include sodium tripolyphosphate.

### Claim 5 (depends on 1)

A device according to claim 1, further comprising a free quantity of the therapeutic agent, embedded directly in the matrix, and not otherwise coated with chitosan, wherein the free quantity of the therapeutic agent constitutes between 20-80% of a total quantity of therapeutic agent in the device.

### Claim 6 (depends on 1)

A device according to claim 1, further comprising a backing layer disposed on the second surface, wherein the backing layer prevents significant loss of payload components in the device from diffusion through the second surface, and optionally protects the device from an environment.

### Claim 7 (depends on 6)

A device according to claim 6, wherein the backing layer includes a material selected from the group consisting of a polyacrylate adhesive, a non-woven polyester fabric backing, and combinations thereof.

### Claim 8 (depends on 1)

A device according to claim 1, wherein the therapeutic agent is a chemotherapeutic pharmaceutical.

### Claim 9 (depends on 8)

A device according to claim 8, wherein the chemotherapeutic is selected from the group consisting of platinum-based chemotherapeutics, 5-flurouracil, and combinations thereof.

### Claim 10 (depends on 1)

A device according to claim 1, wherein the therapeutic agent is an agent selected from the group consisting of anti-infective, anti-bacterial, or anti-viral agent, and combinations thereof.

### Claim 11 (depends on 1)

A kit comprising the device according to claim 1 and a permeation enhancing agent selected from the group consisting of dodecyl-2-(N,N-dimethylamino) propionate, bile salts, surfactants, fatty acids, glycerides, polyacrylic acid derivatives, chelating agents, nitric oxide donors, salicylates, chitosan, zona occludens toxins, and combinations thereof.

### Claim 12 (depends on 11)

A kit according to claim 11, wherein the permeation enhancing agent is selected from the group consisting of sodium cholate, sodium deoxycholate, sodium glycodeoxycholate, sodium taurocholate, sodium glycocholate, N-lauryl-b-maltopyranoside, and combinations thereof.

### Claim 13 (depends on 11)

A kit according to claim 11, wherein the surfactant is selected from the group consisting of oleic acid, sodium dodecyl sulfate, sodium lauryl sulfate, polysorbate 80, lauryl esters, and combinations thereof.

### Claim 14 (depends on 1)

A method for manufacturing a device according to claim 1, the method comprising:
forming a first mixture with a plurality of particles having an average diameter between 500 nm and 2000 nm, the particles containing a therapeutic agent and having a coating around the therapeutic agent, the coating including chitosan;
adding chitosan a particle adhesion inhibitor comprising HPMC, and one or more additives selected from a group consisting of a hydration promoter, a particle aggregation inhibitor and combinations thereof to the first mixture, to form a second mixture;
freezing the second mixture in a bath containing an aqueous alcoholic solution at a temperature above the freezing temperature of the aqueous alcoholic solution and at most −40° C., to form a frozen layer precursor;
drying the frozen layer precursor, to form a porous patch with particles embedded within a polymeric matrix of the patch; and
sterilizing the patch.

### Claim 15 (depends on 14)

A method according to claim 14, wherein the bath further contains dry ice.

### Claim 16 (depends on 14)

A method according to claim 14, wherein the alcohol of the aqueous alcoholic solution is ethanol.

### Claim 17 (depends on 14)

A method according to claim 14, wherein the aqueous alcoholic solution is from about 90 wt % ethanol to about 99 wt % ethanol.

### Claim 18 (depends on 14)

A method according to claim 14, wherein a free quantity of the therapeutic agent is embedded directly in the matrix, and not otherwise coated with chitosan, wherein the free quantity of the therapeutic agent constitutes between 20-80% of a total quantity of therapeutic agent in the device.

### Claim 19 (depends on 14)

A method according to claim 14, wherein the patch includes first and second opposed surfaces and the first surface is configured to be applied to the tissue, the method further comprising adhering a backing layer to the second surface of the patch, wherein the backing layer prevents significant loss of payload components in the patch from diffusion through the second surface, and optionally protects the patch from an environment.

### Claim 20 (depends on 14)

A method according to claim 14, wherein the drying is under vacuum.

### Claim 21 (depends on 14)

A method according to claim 14, wherein the sterilizing includes gamma ray irradiation.